GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CEN Biotech Inc (OTCPK:CENBF) » Definitions » 10-Year RORE %

CEN Biotech (CEN Biotech) 10-Year RORE % : 0.00% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CEN Biotech 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. CEN Biotech does not have enough data to calculate 10-Year RORE %.


CEN Biotech 10-Year RORE % Historical Data

The historical data trend for CEN Biotech's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEN Biotech 10-Year RORE % Chart

CEN Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only - - - - -

CEN Biotech Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CEN Biotech's 10-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, CEN Biotech's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEN Biotech's 10-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CEN Biotech's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where CEN Biotech's 10-Year RORE % falls into.



CEN Biotech 10-Year RORE % Calculation

CEN Biotech's 10-Year RORE % for the quarter that ended in Mar. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2023 and 10-year before.


CEN Biotech  (OTCPK:CENBF) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


CEN Biotech 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of CEN Biotech's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CEN Biotech (CEN Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3295 Quality Way, Suite 300, Windsor, ON, CAN, N8T 3R9
Website
CEN Biotech Inc is an early-stage Canadian biopharmaceutical company. The Company grows, sells, and delivers pharmaceutical-grade medical marijuana to patients.
Executives
Lawrence Lehoux director, officer: Chief Technology Officer 11879 SOLOMAN ST, WINDSOR A6 N8P 1P1
Jeffery Allen Thomas director 23772 WEST ROAD #152, BROWNSTOWN TOWNSHIP MI 48183
Rick Leigh Purdy director 9 ELAINE STREET, ST. ALBERT A0 T8N7R6
Usamakh Saadikh director 3 DRUDBGY NARODOV SQUARE, KYIV 2H 04210
Joseph A. Byrne director, officer: Chief Executive Officer 6 CAMERON SIDE ROAD EAST, ESSEX A6 N8M 2X5
Alex Tarrabain director 18908 89 AVENUE, EDMONTON A0 T5T 6B7
Donald Strilchuck director 352 RIDEAU PL, TECUMSEH A6 N8N 3N9
Richard Boswell director, 10 percent owner, officer: CFO Senior Executive VP 2408 EASTERN AVE., ROCHESTER HILLS MI 48307
Ameen Ferris director 30 AYRSHIRE COURT, BRAMPTON A6 L6Z 0G6
Brian Payne director, officer: Vice President 1027 HUNTINGTON BLVD, BELLE RIVER A6 N0R 1A0
Aubrey De Lavenu Harold Andre director APT 627 VALE DO LOBO, ALMANCIL S1 8135-034
Bahige B. Chaaban director, 10 percent owner, officer: Chief Executive Officer 888 OLD TECUMSAH RD., BELLE RIVER A6 N0R 1A0

CEN Biotech (CEN Biotech) Headlines